GlobeNewswire: Keryx Biopharmaceuticals, Inc. Contains the last 10 of 173 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T08:12:33ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/12/11/1665421/0/en/Keryx-Biopharmaceuticals-Stockholders-Approve-Merger-with-Akebia-Therapeutics.html?f=22&fvtc=4&fvtv=3545Keryx Biopharmaceuticals Stockholders Approve Merger with Akebia Therapeutics2018-12-11T17:00:00Z<![CDATA[BOSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that Keryx stockholders voted in favor of adopting the merger agreement among Keryx and inter alia Akebia Therapeutics, Inc.]]>https://www.globenewswire.com/news-release/2018/11/30/1660055/0/en/Glass-Lewis-Recommends-that-Keryx-Biopharmaceuticals-Stockholders-Vote-FOR-the-Proposed-Merger-with-Akebia-Therapeutics.html?f=22&fvtc=4&fvtv=3545Glass Lewis Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics2018-11-30T13:55:00Z<![CDATA[BOSTON, Nov. 30, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that leading independent proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) recommends Keryx stockholders vote “FOR” the proposals relating to the proposed merger with Akebia Therapeutics, Inc. (Nasdaq: AKBA) at the Special Meeting of Keryx stockholders to be held on December 11, 2018.]]>https://www.globenewswire.com/news-release/2018/11/29/1658819/0/en/ISS-Recommends-that-Keryx-Biopharmaceuticals-Stockholders-Vote-FOR-the-Proposed-Merger-with-Akebia-Therapeutics.html?f=22&fvtc=4&fvtv=3545ISS Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics2018-11-29T12:00:00Z<![CDATA[Leading proxy advisory firm recognizes the strategic and financial merits of the merger Leading proxy advisory firm recognizes the strategic and financial merits of the merger]]>https://www.globenewswire.com/news-release/2018/11/08/1648604/0/en/Keryx-Biopharmaceuticals-Announces-Third-Quarter-2018-Financial-Results.html?f=22&fvtc=4&fvtv=3545Keryx Biopharmaceuticals Announces Third Quarter 2018 Financial Results2018-11-08T21:30:00Z<![CDATA[BOSTON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced its financial results for the third quarter ended September 30, 2018. The company also reviewed its commercial progress with Auryxia and provided a general business update.]]>https://www.globenewswire.com/news-release/2018/11/06/1646501/0/en/Keryx-Biopharmaceuticals-to-Release-Third-Quarter-2018-Financial-Results-on-Thursday-November-8-2018.html?f=22&fvtc=4&fvtv=3545Keryx Biopharmaceuticals to Release Third Quarter 2018 Financial Results on Thursday, November 8, 20182018-11-06T21:30:00Z<![CDATA[BOSTON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that it will release its third quarter 2018 financial results on Thursday, November 8, 2018 at approximately 4:30 p.m. ET.]]>https://www.globenewswire.com/news-release/2018/10/30/1639799/0/en/Keryx-Biopharmaceuticals-Announces-Filing-of-Definitive-Joint-Proxy-Statement-in-Connection-with-Pending-Merger-with-Akebia-Therapeutics.html?f=22&fvtc=4&fvtv=3545Keryx Biopharmaceuticals Announces Filing of Definitive Joint Proxy Statement in Connection with Pending Merger with Akebia Therapeutics2018-10-30T21:31:00Z<![CDATA[Keryx Board Unanimously Supports Merger with Akebia and Encourages Stockholders to vote “FOR” the Merger Proposals]]>https://www.globenewswire.com/news-release/2018/10/01/1587857/0/en/Keryx-Biopharmaceuticals-Announces-Participation-in-an-Upcoming-Investor-Conference.html?f=22&fvtc=4&fvtv=3545Keryx Biopharmaceuticals Announces Participation in an Upcoming Investor Conference2018-10-01T13:16:41Z<![CDATA[BOSTON, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that it will participate in the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 in New York.]]>https://www.globenewswire.com/news-release/2018/08/08/1548758/0/en/Keryx-Biopharmaceuticals-Announces-Second-Quarter-2018-Financial-Results.html?f=22&fvtc=4&fvtv=3545Keryx Biopharmaceuticals Announces Second Quarter 2018 Financial Results 2018-08-08T11:00:00Z<![CDATA[BOSTON, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced its financial results for the second quarter ended June 30, 2018. The company also reviewed its commercial progress with Auryxia and provided a general business update.]]>https://www.globenewswire.com/news-release/2018/08/02/1546638/0/en/Keryx-Biopharmaceuticals-to-Host-Conference-Call-of-Second-Quarter-2018-Financial-Results-on-Wednesday-August-8-2018.html?f=22&fvtc=4&fvtv=3545Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2018 Financial Results on Wednesday, August 8, 20182018-08-02T20:05:00Z<![CDATA[BOSTON, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that it will host a conference call and webcast on Wednesday, August 8, 2018 at 8:00 a.m. ET to discuss its second quarter 2018 financial results and provide a business update.]]>https://www.globenewswire.com/news-release/2018/06/20/1527293/0/en/Keryx-Biopharmaceuticals-Announces-Participation-in-a-Renal-Disease-Panel-at-the-JMP-Securities-Life-Sciences-Conference-on-Thursday-June-21st.html?f=22&fvtc=4&fvtv=3545Keryx Biopharmaceuticals Announces Participation in a Renal Disease Panel at the JMP Securities Life Sciences Conference on Thursday, June 21st2018-06-20T13:21:03Z<![CDATA[BOSTON, June 20, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced participating in an upcoming panel in New York City.]]>